Following the publication of multiple studies confirming that Elmiron vision loss is a real risk for those taking the popular medication, the U.S. Food and Drug Administration has posted a warning label that indicates the dangers of retinal pigmentary changes and cases of maculopathy.
The woman who is considered to be “Patient Zero” in the groundbreaking study that revealed the depths of Elmiron vision loss has now filed a personal injury lawsuit against the drug’s manufacturer in the Superior Court of New Jersey, Middlesex County. She is seeking damages from Janssen Pharmaceuticals and several other Johnson * Johnson and Teva Pharmaceuticals companies involved in the production, marketing and distribution of the drug for the retinal damage that she suffered.
Imagine taking medication for nearly 15 years to address relentless pain, only to find that it has led to permanent vision loss. That is exactly what Kimberly Pelczar says happened to her. The Connecticut woman has filed an Elmiron vision loss lawsuit against both Teva Pharmaceuticals USA Inc., and Johnson & Johnson’s subsidiary Janssen Pharmaceuticals, accusing both of negligence and responsibility for her eye problems.
A Canadian woman who has long suffered from interstitial cystitis found remarkable relief from the condition, but now she is voluntarily returning to her discomfort out of fear of Elmiron vision loss. Carrie Gagno lives in Toronto, Canada. She has been taking Elmiron – also known by its generic name of pentosan polysulfate sodium – for 15 years, ever since her physician prescribed it for the painful bladder syndrome. But now that her physician has learned of its risk and made her aware, she has voluntarily given up the medication.
Despite receiving many reports from consumers about Elmiron vision loss, Janssen Pharmaceuticals, Inc. and Johnson & Johnson continued marketing the prescription drug to people suffering from interstitial cystitis and bladder pain, providing them with no warnings or notice about the dangers posed by the medication. Even after multiple scientific papers have been published in medical literature and making changes to labeling in other countries, warning users of the potential for injury, the companies made no such changes in the United States.
There are an estimated 200,000 Americans diagnosed with interstitial cystitis every year, and for many of those who suffer with this painful bladder syndrome, news of the Elmiron vision loss risk was devastating. The medication has been highly successful in offering relief to those who had previously endured the chronic pain of the condition, and who are now seeking alternative treatments.
When Connecticut resident Kimberly Pelczar’s physician prescribed her medication to treat her painful symptoms of interstitial cystitis, neither the physician nor the patient was aware of the risk of Elmiron vision loss. But according to a personal injury lawsuit that Ms. Pelczar recently filed in the U.S. District Court in the District of Connecticut, the drug’s manufacturers were aware of the drug’s dangers and of previous injuries suffered by other patients but chose to keep the information quiet. The woman is seeking damages for the permanent vision loss that she suffered.
Last fall, a study conducted by ophthalmologists at Kaiser Permanente in Northern California shocked the medical world and started a cascade of Elmiron vision loss lawsuits. The initial indication that Elmiron, a popular bladder condition medication, might be causing eye problems came from Nieraj Jain, M.D. of Emory Eye Center. After he reported that several patients taking the drug over a sustained period of time had suffered damage to their retina, three ophthalmologists from Kaiser began a study, which confirmed his suspicions.
Danziger & De Llano, LLP. Office Locations: (Principal Office) Houston, Texas . Contact Danziger & De Llano for more information. Prior results do not guarentee or predict a similar outcome with respect to any future matter.